natgillin/translations-raw huggingface dataset:
• The dose for Stocrin may need to be increased or decreased if you are also taking certain medicines (see Other medicines and Stocrin). 
• Dozu lijeka Stocrin možda će trebati povisiti ili sniziti ako uzimate i neke druge lijekove
In order to improve the tolerability of nervous system adverse reactions, bedtime dosing is recommended during the first two to four weeks of therapy and in patients who continue to experience these symptoms (see section 4.8). 
Radi lakšeg podnošenja nuspojava živčanog sustava, preporučuje se uzimanje lijeka prije spavanja u prva dva do četiri tjedna liječenja te u bolesnika koji i nakon toga imaju navedene simptome (vidjeti dio 4.8).
Each carton contains 1 bottle of 30 film-coated tablets. 
Jedna kutija sadrži 1 bocu s 30 filmom obloženih tableta.
Sofosbuvir/velpatasvir sofosbuvir/velpatasvir/voxilaprevir 
Sofosbuvir/velpatasvir sofosbuvir/velpatasvir/voksilaprevir sofosbuvir: Cmax ↑38%
 Efavirenz 50 mg, 200 mg and 600 mg film-coated tablets are available. 
* dostupne su efavirenz 50 mg, 200 mg i 600 mg filmom obložene tablete.
AUC: ↑ 11 % (↑ 5 to ↑ 18) Cmax: ↑ 16 % (↑ 6 to ↑ 26) Cmin: ↑ 13 % (↑ 1 to ↑ 26) (CYP3A4 induction) The increase in efavirenz pharmacokinetic parameters is not considered clinically significant. 
AUC: ↑ 11% (↑ 5 do ↑ 18) Cmax: ↑ 16% (↑ 6 do ↑ 26) Cmin: ↑ 13% (↑ 1 do ↑ 26) (indukcija CYP3A4) Povišenje vrijednosti farmakokinetičkih parametara efavirenza ne smatra se klinički značajnim.
Nervous system symptoms of moderate-to-severe intensity were experienced by 19 % (severe 2.0 %) of patients compared to 9 % (severe 1 %) of patients receiving control regimens. 
Simptomi živčanog sustava umjerenog do jakog intenziteta zabilježeni su u 19% bolesnika koji su primali efavirenz (teški 2%), u odnosu na 9% bolesnika u kontrolnoj skupini (teški 1%).
Table 1 Paediatric dose to be administered once daily* 
Tablica 1 Doza za djecu koju treba primjenjivati jedanput na dan*
Stocrin is not recommended for children under the age of 3 years or weighing less than 13 kg because it has not been adequately studied in these patients. 
Stocrin se ne preporučuje za djecu mlađu od 3 godine ili djecu tjelesne težine manje od 13 kg jer u tih bolesnika nije ispitan na odgovarajući način.
Autoimmune disorders (such as Graves' disease and autoimmune hepatitis) have also been reported to occur in the setting of immune reactivation; however, the reported time to onset is more variable and these events can occur many months after initiation of treatment. 
U uvjetima imunološke reaktivacije prijavljeni su i autoimuni poremećaji (kao npr. Gravesova bolest i autoimuni hepatitis); međutim, prijavljeno vrijeme do pojave je različito i ti se događaji mogu javiti više mjeseci nakon uvođenja liječenja.
A multiple-dose study showed no significant effect on efavirenz pharmacokinetics in patients with mild hepatic impairment (Child-Pugh Class A) compared with controls. 
Ispitivanje s višekratnim dozama nije pokazalo značajan učinak na farmakokinetiku efavirenza u bolesnika s blagim oštećenjem funkcije jetre (Child-Pugh stadij A) u odnosu na kontrolnu skupinu.
AUC: ↑ 20 % (↑ 8 to ↑ 34) Cmax: ↑ 21 % (↑ 10 to ↑ 33) The combination was generally well tolerated. 
AUC: ↑ 20% (↑ 8 do ↑ 34) Cmax: ↑ 21% (↑ 10 do ↑ 33) Ova se kombinacija općenito dobro podnosila.
AUC: ↔* (↓ 9 to ↑ 10) Cmax: ↑ 17 %* (↑ 8 to ↑ 27) Cmin: ↓ 42 %* (↓ 31 to ↓ 51) 
AUC: ↔* (↓ 9 do ↑ 10) Cmax: ↑ 17%* (↑ 8 do ↑ 27) Cmin: ↓ 42%* (↓ 31 do ↓ 51)
AUC: ↓ 36 % C12: ↓ 21 % Cmax: ↓ 36 % (UGT1A1 induction) 
AUC: ↓ 36% C12: ↓ 21% Cmax: ↓ 36% (indukcija UGT1A1)
AUC: ↑ 7 % (↑ 1 to ↑ 14) Cmax: ↑ 16 % (↑ 2 to ↑ 32) These changes are not considered clinically significant. 
AUC: ↑ 7% (↑ 1 do ↑ 14) Cmax: ↑ 16% (↑ 2 do ↑ 32) Ove se promjene ne smatraju klinički značajnima.
Amylase: in the clinical trial subset of 1,008 patients, asymptomatic increases in serum amylase levels greater than 1.5 times the upper limit of normal were seen in 10 % of patients treated with efavirenz and 6 % of patients treated with control regimens. 
Amilaza: u podskupini od 1008 bolesnika u kliničkom ispitivanju opaženo je asimptomatsko povišenje vrijednosti amilaze u serumu više od 1,5 puta iznad gornje granice normale u 10% bolesnika liječenih efavirenzom i u 6% bolesnika u kontrolnom protokolu.
Liver enzymes in hepatitis B or C co-infected patients In the long-term data set from study 006, 137 patients treated with efavirenz-containing regimens (median duration of therapy, 68 weeks) and 84 treated with a control regimen (median duration, 56 weeks) were seropositive at screening for hepatitis B (surface antigen positive) and/or C (hepatitis C antibody positive). 
Jetreni enzimi u bolesnika istodobno zaraženih virusom hepatitisa B ili C Prema podacima dugoročnog ispitivanja iz ispitivanja 006, 137 bolesnika na protokolu koji je uključivao efavirenz (medijan trajanja terapije 68 tjedana) i 84 bolesnika na kontrolnom protokolu (medijan trajanja 56 tjedana) bilo je seropozitivno na probiru na hepatitis B (pozitivan površinski antigen) i/ili hepatitis C (pozitivno protutijelo na hepatitis C).
STOCRIN is indicated in antiviral combination treatment of human immunodeficiency virus-1 (HIV-1) infected adults, adolescents and children 3 years of age and older. 
STOCRIN je indiciran u kombiniranom antivirusnom liječenju odraslih, adolescenata i djece u dobi od 3 godine i starije zaraženih virusom humane imunodeficijencije tipa 1 (HIV-1).
• Stocrin oral solution may be taken with or without food. 
•Stocrin oralna otopina može seuzimati shranom ili bez nje.
STOCRIN 200 mg film-coated tablets Yellow, round, debossed with “223” on one side. 
STOCRIN 200 mg filmom obložene tablete Žuta, okrugla, s utisnutom oznakom "223" na jednoj strani.
This effect is due to an induction of CYP3A4 or P-gp by efavirenz and is expected to result in the loss of virologic response of elbasvir/grazoprevir. 
Do ovog učinka dolazi zbog indukcije CYP3A4 ili P-glikoproteina (P-gp) efavirenzom te se očekuje da će ta indukcija dovesti do gubitka virološkog odgovora elbasvira/grazoprevira.
• The dose for adults is 24 ml once daily. 
•Doza lijeka za odrasle je 24ml jedanput na dan.
The dose of Stocrin oral solution must be measured using the oral syringe supplied in the carton. 
Dozu Stocrin oralne otopine morate odmjeriti pomoću štrcaljke za oralnu primjenu koja se nalazi u pakiranju.
The AUC and Cmax of a single 600 mg dose of efavirenz film-coated tablets in uninfected volunteers was increased by 28 % (90 % CI: 22 - 33 %) and 79 % (90 % CI:58 - 102 %), respectively, when given with a high fat meal relative to when given under fasted conditions (see section 4.4). 
Nakon primjene jednokratne doze od 600 mg efavirenz filmom obloženih tableta s punomasnim obrokom u nezaraženih dobrovoljaca AUC je porastao 28% (90% Cl: 22-33%), a Cmax 79% (90% Cl: 58-102%) u usporedbi s primjenom lijeka natašte (vidjeti dio 4.4).
The AUC and Cmax of a single 240 mg dose of efavirenz oral solution in uninfected adult volunteers was increased by 30 % and 43 % respectively, when given with a high-fat meal, relative to fasted conditions. 
Nakon primjene jednokratne doze od 240 mg oralne otopine efavirenza s punomasnim obrokom u nezaraženih odraslih dobrovoljaca AUC je porastao 30%, a Cmax 43% u usporedbi s primjenom lijeka natašte.
There have also been post-marketing reports of severe depression, death by suicide, delusions, psychosis-like behaviour and catatonia. 
Nakon stavljanja lijeka u promet prijavljeni su slučajevi teške depresije, samoubojstava, deluzija, psihotičnog ponašanja i katatonije.
In 17 paediatric patients receiving an investigational oral solution similar to the commercial formulation adjusted on the basis of body size to be equivalent to an adult 600 mg capsule dose, the steady-state Cmax was 11.8 M, steady state Cmin was 5.2 M, and AUC was 188 M·h. 
U 17 pedijatrijskih bolesnika koji su primili ispitivanu oralnu otopinu koja je bila slična onoj dostupnoj na tržištu, u dozi prilagođenoj prema veličini tijela tako da odgovara dozi za odrasle od 600 mg u obliku tvrde kapsule, Cmax u stanju dinamičke ravnoteže iznosio je 11.8 M, Cmin je bio 5.2 M, a AUC 188 M·h.
If efavirenz and telaprevir are coadministered, telaprevir 1,125 mg every 8 hours should be used. 
Ako se efavirenz i telaprevir primjenjuju istodobno, telaprevir u dozi od 1125 mg treba primijeniti svakih 8 sati.
Sertraline(a medicine used to treat depression):your doctor may need to change your dose of sertraline. 
sertralin (lijek koji se koristi za liječenje depresije): liječnik će Vam možda trebati promijeniti dozu sertralina.
Co-administration of efavirenz with a fixed combination tablet containing efavirenz, emtricitabine, and tenofovir disoproxil, is not recommended unless needed for dose adjustment (for example, with rifampicin). 
Ne preporučuje se istodobna primjena efavirenza s tabletama koje sadrže fiksnu kombinaciju efavirenza, emtricitabina i tenofovirdizoproksila,osim ako nije potrebno zbog prilagodbe doze (na primjer, s rifampicinom).
• The dose for children weighing 40 kg or more is 600 mg once daily. 
• Doza lijeka za djecu tjelesne težine 40 kg ili više je 600 mg jedanput na dan.
The administration of efavirenz with food may increase efavirenz exposure (see section 5.2) and may lead to an increase in the frequency of adverse reactions (see section 4.8). 
Primjena efavirenza s hranom može povećati izloženost efavirenzu (vidjeti dio 5.2) i može povećati učestalost nuspojava (vidjeti dio 4.8).
The recommended dose of efavirenz in combination with nucleoside analogue reverse transcriptase inhibitors (NRTIs) with or without a PI (see section 4.5) is 24 ml orally, once daily. 
Preporučena doza efavirenza u kombinaciji s nukleozidnim analozima inhibitora reverzne transkriptaze (engl. nucleoside analogue reverse transcriptase inhibitors, NRTI), s inhibitorom proteaze ili bez njega (vidjeti dio 4.5), jest 24 mg peroralno, jedanput na dan.
Excipient with known effect Each film-coated tablet contains 249.6 mg of lactose (as monohydrate). 
Pomoćna tvar s poznatim učinkom Jedna filmom obložena tableta sadrži 249,6 mg laktoze (u obliku hidrata).
Peak efavirenz plasma concentrations of 1.6 - 9.1 M were attained by 5 hours following single oral doses of 100 mg to 1,600 mg administered to uninfected volunteers. 
Vršne koncentracije efavirenza u plazmi od 1,6-9,1 µM dostignute su u nezaraženih dobrovoljaca do 5 sati nakon jednokratne primjene oralnih doza lijeka od 100 do 1600 mg.
The net effect of co-administration is not clear. 
Neto učinak istodobne primjene nije razjašnjen.
In HIV infected patients with severe immune deficiency at the time of initiation of combination antiretroviral therapy (CART), an inflammatory reaction to asymptomatic or residual opportunistic infections may arise. 
U bolesnika zaraženih virusom HIV-a s teškom imunodeficijencijom u trenutku uvođenja kombinirane antiretrovirusne terapije može se razviti upalna reakcija na asimptomatske ili rezidualne oportunističke infekcije.
Liver enzymes: elevations of AST and ALT to greater than five times the upper limit of the normal range (ULN) were seen in 3 % of 1,008 patients treated with 600 mg of efavirenz (5-8 % after long-term treatment in study 006). 
Jetreni enzimi: povišene vrijednosti AST-a i ALT-a više od pet puta iznad gornje granice normale (GGN) opažene su u 3% od 1008 bolesnika liječenih efavirenzom u dozi od 600 mg (5-8% nakon dugotrajnog liječenja u ispitivanju 006).
In 49 paediatric patients receiving the equivalent of a 600 mg dose of efavirenz (dose adjusted from calculated body size based on weight), steady state Cmax was 14.1 M, steady state Cmin was 5.6 M, and AUC was 216 M·h. 
U 49 djece koja su primala efavirenz u dozi koja je odgovarala dozi od 600 mg (prilagođeno prema izračunatoj veličini tijela na temelju tjelesne težine) u stanju dinamičke ravnoteže Cmax je iznosio 14,1 μM, Cmin 5,6 μM, a AUC 216 μM·h.
AUC: ↓ 31 % (↓ 8 to ↓ 47) Cmin: ↓ 40 % 
AUC: ↓ 31% (↓ 8 do ↓ 47) Cmin: ↓ 40%
In order to improve the tolerability of nervous system adverse reactions, bedtime dosing is recommended (see section 4.8). 
Radi lakšeg podnošenja nuspojava živčanog sustava, preporučuje se uzimanje lijeka prije spavanja (vidjeti dio 4.8).
To do this, remove the child-resistant cap and the foil seal. 
Da biste to učinili, skinite sigurnosni zatvarač za djecu s boce i odstranite zaštitnu foliju.
STOCRIN has not been adequately studied in patients with advanced HIV disease, namely in patients with CD4 counts < 50 cells/mm 
STOCRIN nije adekvatno ispitan u bolesnika s uznapredovalom HIV bolešću, odnosno u bolesnika s <50 CD4 stanica/mm
The recommended dose of efavirenz in combination with nucleoside analogue reverse transcriptase inhibitors (NRTIs) with or without a PI (see section 4.5) is 600 mg orally, once daily. 
Preporučena doza efavirenza u kombinaciji s nukleozidnim analozima inhibitora reverzne transkriptaze (engl. nucleoside analogue reverse transcriptase inhibitors, NRTI), s inhibitorom proteaze ili bez njega (vidjeti dio 4.5), jest 600 mg peroralno, jedanput na dan.
AUC: ↓ 83 % (↓ 79 to ↓ 87) Cmax: ↓ 80 % (↓ 77 to ↓ 83) Cmin: ↓ 86 % (↓ 80 to ↓ 90) (induction of metabolism) Efavirenz: no clinically significant interaction. 
AUC: ↓ 83% (↓ 79 do ↓ 87) Cmax: ↓ 80% (↓ 77 do ↓ 83) Cmin: ↓ 86% (↓ 80 do ↓ 90) (indukcija metabolizma) efavirenz: nema klinički značajnih interakcija.
The pharmacokinetics of efavirenz in paediatric patients were similar to adults. 
Farmakokinetika efavirenza u djece bila je slična onoj u odraslih bolesnika.
Co-administration of glecaprevir/pibrentasvir with efavirenz is not recommended (see section 4.5). 
Ne preporučuje se istodobna primjena glekaprevira/pibrentasvira s efavirenzom (vidjeti dio 4.5).
The adapter should now fit closely to the neck so that the cap can be replaced without removing it. 
Nastavak mora biti čvrsto priljubljen uz grlo boce tako da se boca može ponovno zatvoriti bez skidanja nastavka.
Pregnancies have occurred in women taking Stocrin while using a contraceptive implant, although it has not been established that the Stocrin therapy caused the contraceptive to fail. 
Trudnoće su nastupile u žena koje su uzimale Stocrin i koristile kontracepcijski implantat, premda nije utvrđeno da liječenje lijekom Stocrin sprječava djelovanje kontraceptiva.
• The dose for children weighing 40 kg or more is 24 ml once daily. 
• Doza lijeka za djecu tjelesne težine 40 kg ili više je 24 ml jedanput na dan.
Stocrin may reduce the amount of voriconazole in your blood and voriconazole may increase the amount of Stocrin in your blood. 
Stocrin može smanjiti koncentraciju vorikonazola u krvi, a vorikonazol može povećati koncentraciju lijeka Stocrin u krvi.
‡, disturbance in attention (3.6 %), dizziness (8.5 %), headache (5.7 %), somnolence uncommon agitation, amnesia, ataxia, coordination abnormal, convulsions, thinking abnormal, tremor 
‡, poremećaj pažnje (3,6%), omaglica (8,5%), glavobolja (5,7%), somnolencija (2,0%)*
If efavirenz is coadministered with voriconazole, the voriconazole maintenance dose must be increased to 400 mg every 12 hours and the efavirenz dose must be reduced by 50 %, i.e., to 300 mg once daily. 
Ako se efavirenz primjenjuje istodobno s vorikonazolom doza održavanja vorikonazola mora se povisiti na 400 mg svakih 12 sati, a doza efavirenza mora se sniziti za 50%, tj. na dozu od 300 mg jedanput na dan.
Long-term results at 168 weeks of study 006 (160 patients completed study on treatment with EFV +IDV, 196 patients with EFV + ZDV + 3TC and 127 patients with IDV + ZDV + 3TC, respectively), suggest durability of response in terms of proportions of patients with HIV RNA < 400 copies/ml, HIV RNA < 50 copies/ml and in terms of mean change from baseline CD4 cell count. 
Dugoročni rezultati nakon 168 tjedana ispitivanja 006 (ispitivanje je završilo 160 bolesnika liječenih kombinacijom EFV + IDV, 196 bolesnika liječenih kombinacijom EFV + ZDV + 3TC te 127 bolesnika liječenih kombinacijom IDV + ZDV + 3TC) pokazuju održanost odgovora na liječenje s obzirom na udio bolesnika s HIV-RNK < 400 kopija/ml, HIV-RNK < 50 kopija/ml te s obzirom na srednju vrijednost promjene od početnog broja CD4 stanica.
EU/1/99/111/005 - bottle 
EU/1/99/111/005 - boca
Fosamprenavir/Nelfinavir/Efavirenz Interaction not studied 
fosamprenavir/nelfinavir/efavirenz Interakcija nije ispitivana.
Co-administration with terfenadine, astemizole, cisapride, midazolam, triazolam, pimozide, bepridil, or ergot alkaloids (for example, ergotamine, dihydroergotamine, ergonovine, and methylergonovine) because competition for CYP3A4 by efavirenz could result in inhibition of metabolism and create the potential for serious and/or life-threatening adverse reactions [for example, cardiac arrhythmias, prolonged sedation or respiratory depression] (see section 4.5). 
Istodobna primjena s terfenadinom, astemizolom, cisapridom, midazolamom, triazolamom, pimozidom, bepridilom niti ergot alkaloidima (npr. ergotaminom, dihidroergotaminom, ergonovinom i metilergonovinom) jer kompeticija efavirenza za CYP3A4 može uzrokovati inhibiciju metabolizma i stvoriti mogućnost pojave ozbiljnih i/ili po život opasnih nuspojava [npr. srčanih aritmija, produljene sedacije ili respiratorne depresije] (vidjeti dio 4.5).
You should not breast feed your baby if you are taking Stocrin. 
Ne smijete dojitiVaše dojenčeako uzimate Stocrin.
When efavirenz is co-administered with voriconazole, the voriconazole maintenance dose must be increased to 400 mg twice daily and the efavirenz dose must be reduced by 50 %, i.e., to 300 mg once daily. 
Kad se efavirenz primjenjuje istodobno s vorikonazolom, doza održavanja vorikonazola mora se povisiti na 400 mg dvaput na dan, dok se doza efavirenza mora sniziti za 50%, tj. na 300 mg jedanput na dan.
If you are affected your doctor may suggest that you take Stocrin at bedtime. 
Ako se u Vas pojave opisani simptomi, liječnik Vam može predložiti da Stocrin uzimate prije spavanja.
Fosamprenavir/Saquinavir/Efavirenz Interaction not studied 
fosamprenavir/sakvinavir/efavirenz Interakcija nije ispitivana.
The recommended dose of efavirenz in combination with a PI and/or NRTIs for patients between 3 and 17 years of age is described in Table 1. 
Preporučene doze efavirenza u kombinaciji s inhibitorom proteaze i/ili NRTI-ma za bolesnike u dobi između 3 i 17 godina prikazane su u Tablici 1.
Integrase strand transfer inhibitor Raltegravir/Efavirenz (400 mg single dose/ - ) 
Inhibitori integraze raltegravir/efavirenz (400 mg u jednokratnoj dozi/ -)
Cmax: ↑ 11 % (↑ 6 to ↑ 16) Cmin: ↔ (CYP3A4 induction) 
Cmax: ↑ 11% (↑ 6 do ↑ 16) Cmin: ↔ (indukcija CYP3A4)
Ear and labyrinth disorders uncommon tinnitus 
Poremećaji uha i labirinta manje često tinitus
Cmin: ↓ 12 % (↓ 24 to ↑ 1) (CYP3A4 induction) 
Cmin: ↓ 12% (↓ 24 do ↑ 1) (indukcija CYP3A4)
STOCRIN 600 mg film-coated tablets STOCRIN 50 mg film-coated tablets STOCRIN 200 mg film-coated tablets 
STOCRIN 600 mg filmom obložene tablete STOCRIN 50 mg filmom obložene tablete STOCRIN 200 mg filmom obložene tablete
Excipient with known effect Each film-coated tablet contains 20.8 mg of lactose (as monohydrate). 
Pomoćna tvar s poznatim učinkom Jedna filmom obložena tableta sadrži 20,8 mg laktoze (u obliku hidrata).
Tablet core: Croscarmellose sodium, Microcrystalline cellulose, Sodium laurilsulfate, Hydroxypropylcellulose, Lactose monohydrate, Magnesium stearate 
Jezgra tablete: karmelozanatrij, umrežena; celuloza, mikrokristalična; natrijev laurilsulfat; hidroksipropilceluloza; laktoza hidrat; magnezijev stearat
180 ml oral solution Oral syringe with a pushin bottleneck adapter. 
180 ml oralne otopine Oralna štrcaljka s nastavkom za bocu koji se utisne u grlo boce.
AUC: ↑ 34 % (↑ 18 to ↑ 53) Cmax: ↑ 49 % (↑ 32 to ↑ 69) Efavirenz: 
14-hidroksimetabolit: AUC: ↑ 34% (↑ 18 do ↑ 53) Cmax: ↑ 49% (↑ 32 do ↑ 69) efavirenz:
Table 1 Paediatric dose to be administered once daily 
Tablica 1 Doza za djecu koju treba primjenjivati jedanput na dan
Medicines used to treat malaria: artemether/lumefantrine: Stocrin may reduce the amount of artemether/lumefantrine in your blood. 
lijekove koji se koriste za liječenje malarije: artemeter/lumefantrin: Stocrin može smanjiti koncentraciju artemetera/lumefantrina u krvi atovakvon/progvanil: Stocrin može smanjiti koncentraciju atovakvona/progvanila u krvi.
A similar reduction in indinavir exposures was observed when indinavir 1,000 mg q8h was given with efavirenz 600 mg daily. 
Slično smanjenje izloženosti indinaviru opaženo je kad se indinavir 1000 mg svakih 8h primjenjivao s efavirenzom 600 mg na dan. (indukcija CYP3A4) efavirenz:
Malformations were observed in 3 of 20 foetuses/newborns from efavirenz-treated cynomolgus monkeys given doses resulting in plasma efavirenz concentrations similar to those seen in humans. 
U ženki makaki majmuna koje su primale efavirenz zabilježene su malformacije u 3 od 20 plodova/novookoćenih majmuna pri koncentraciji efavirenza u plazmi sličnoj onoj u ljudi.
AUC: ↓ 4 % (↓ 0 to ↓ 31) Cmax: ↓ 47 % (↓ 9 to ↓ 51) Total active HMG Co-A reductase inhibitors: 
AUC: ↓ 4% (↓ 0 do ↓ 31) Cmax: ↓ 47% (↓ 9 do ↓ 51) Ukupno aktivni inhibitori HMG Co-A reduktaze:
STOCRIN 600 mg film-coated tablets Dark yellow, capsule-shaped, debossed with “225” on one side. 
STOCRIN 600 mg filmom obložene tablete Tamnožuta, u obliku kapsule, s utisnutom oznakom "225" na jednoj strani.
Elevations of GGT to greater than five times ULN were observed in 4 % of all patients treated with 600 mg of efavirenz and 1.5 - 2 % of patients treated with control regimens (7 % of efavirenz-treated patients and 3 % of control-treated patients after long-term treatment). 
Porast vrijednosti GGT-a više od pet puta iznad gornje granice normale zabilježen je u 4% svih bolesnika koji su primali efavirenz u dozi od 600 mg i u 1,5-2% bolesnika liječenih kontrolnim protokolom (nakon dugotrajnog liječenja u 7% ispitanika koji su primali efavirenz i u 3% ispitanika u kontrolnom protokolu).
AUC: ↓ 39 % (↓ 30 to ↓ 46) Cmax: ↓ 26 % (↓ 15 to ↓ 35) Clarithromycin 
AUC: ↓ 39% (↓ 30 do ↓ 46) Cmax: ↓ 26% (↓ 15 do ↓ 35) klaritromicin
Carbamazepine may make Stocrin less likely to work. 
Karbamazepin može smanjiti djelotvornost lijeka Stocrin.
Among co-infected patients in study 006, elevations in AST to greater than five times ULN developed in 13 % of efavirenz treated patients and in 7 % of controls, and elevations in ALT to greater than five times ULN developed in 20 % and 7 % respectively. 
Među koinficiranim bolesnicima u ispitivanju 006 porast AST-a više od pet puta iznad GGN zabilježen je u 13% bolesnika koji su primali efavirenz i u 7% u kontrolnoj skupini, a porast ALT-a više od pet puta iznad GGN zabilježen je u 20% bolesnika na efavirenzu i u 7% bolesnika u kontrolnoj skupini.
(500/125 mg twice daily/600 mg once daily) 
(500/125 mg dvaput na dan/600 mg jedanput na dan)
Efavirenz has been shown to be excreted in human milk. 
Efavirenz se izlučuje u majčino mlijeko.
- if you have a history of convulsions (fits or seizures) or if you are being treated with anticonvulsant therapy such as carbamazepine, phenobarbital and phenytoin. 
- ako ste nekada imali konvulzije (napadaje) ili se liječite antikonvulzivnim lijekovima kao što su karbamazepin, fenobarbital i fenitoin.
AUC: ↓ 58 % (↓ 39 to ↓ 68) Cmax: ↓ 51 % (↓ 32 to ↓ 58) Total active HMG Co-A reductase inhibitors: 
AUC: ↓ 58% (↓ 39 do ↓ 68) Cmax: ↓ 51% (↓ 32 do ↓ 58) Ukupno aktivni inhibitori HMG Co-A reduktaze:
Artemether/lumefantrine/ Efavirenz (20/120 mg tablet, 6 doses of 4 tablets each over 3 days/600 mg once daily) 
Antimalarici artemeter/lumefantrin/efavirenz (20/120 mg tableta, 6 doza od po 4 tablete, tijekom 3 dana/600 mg jedanput na dan)
Excipient with known effect Each film-coated tablet contains 83.2 mg of lactose (as monohydrate). 
Pomoćna tvar s poznatim učinkom Jedna filmom obložena tableta sadrži 83,2 mg laktoze (u obliku hidrata).
In uninfected volunteers, multiple doses of 200 - 400 mg per day for 10 days resulted in a lower than predicted extent of accumulation 
U nezaraženih je dobrovoljaca primjena višekratnih doza efavirenza od 200-400 mg na dan tijekom 10 dana dovela do manje akumulacije lijeka od predviđene (22-42% niže) i kraćeg terminalnog poluvremena u usporedbi s primjenom jednokratne doze (vidjeti niže).